{"id":"cetrimonium","rwe":[],"tags":[{"label":"cetrimonium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dynamin-1","category":"target"},{"label":"DNM1","category":"gene"},{"label":"D08AJ02","category":"atc"},{"label":"Extracorporeal","category":"route"},{"label":"Liquid","category":"form"},{"label":"Active","category":"status"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Local","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cetrimonium bromide","cetrimonium"],"offLabel":[],"synonyms":["cetrimonium bromide","cetrimonium"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Dynamin-1","targets":[{"gene":"DNM1","source":"DrugCentral","target":"Dynamin-1","protein":"Dynamin-1"}],"modality":"Small Molecule","drugClass":"cetrimonium","explanation":"Imagine Dynamin-1 as a key that helps cells break down and recycle their components. CETRIMONIUM is like a lock that binds to this key, altering the way cells function. This interaction can potentially affect various cellular processes, but the exact effects are still unknown.","oneSentence":"CETRIMONIUM works by interacting with Dynamin-1 to modulate cellular processes.","technicalDetail":"CETRIMONIUM binds to Dynamin-1, a GTPase involved in membrane trafficking and cellular homeostasis, thereby modulating its activity and influencing downstream cellular processes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3082","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CETRIMONIUM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CETRIMONIUM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:32:11.905841","biosimilars":[],"competitors":[{"drugName":"benzalkonium","drugSlug":"benzalkonium","fdaApproval":"","relationship":"same-class"},{"drugName":"cetylpyridinium","drugSlug":"cetylpyridinium","fdaApproval":"","relationship":"same-class"},{"drugName":"benzethonium","drugSlug":"benzethonium","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cetrimonium","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzalkonium","brandName":"benzalkonium","genericName":"benzalkonium","approvalYear":"","relationship":"same-class"},{"drugId":"cetylpyridinium","brandName":"cetylpyridinium","genericName":"cetylpyridinium","approvalYear":"","relationship":"same-class"},{"drugId":"benzethonium","brandName":"benzethonium","genericName":"benzethonium","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07264686","phase":"PHASE2","title":"Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-11-03","conditions":["Cutaneous Ulcer Disease","Skin Sores"],"enrollment":222,"completionDate":"2026-03-30"},{"nctId":"NCT06616844","phase":"NA","title":"IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"ConvaTec Inc.","startDate":"2025-02-12","conditions":["Wound Heal","Ulcer"],"enrollment":194,"completionDate":"2026-07"},{"nctId":"NCT04450693","phase":"PHASE3","title":"Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2020-11-20","conditions":["Diabetic Foot Infection","Non-healing Wound","Non-healing Diabetic Foot Ulcer"],"enrollment":106,"completionDate":"2025-03-24"},{"nctId":"NCT06690814","phase":"PHASE2","title":"Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2024-10-04","conditions":["Cutaneous Ulcer Disease","Skin Sores"],"enrollment":370,"completionDate":"2024-11-01"},{"nctId":"NCT04176120","phase":"PHASE3","title":"Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2020-07-01","conditions":["Diabetic Foot Infection","Non-healing Wound","Non-healing Diabetic Foot Ulcer"],"enrollment":220,"completionDate":"2024-06-12"},{"nctId":"NCT05642767","phase":"","title":"Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-12-01","conditions":["Pseudomonas Aeruginosa"],"enrollment":75,"completionDate":"2023-05-01"},{"nctId":"NCT01726166","phase":"NA","title":"Suprapubic Aspiration Versus Urinary Catheterization In Neonates.","status":"TERMINATED","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2013-04","conditions":["Neonatal Urinary Tract Infection"],"enrollment":49,"completionDate":"2016-05"},{"nctId":"NCT03865147","phase":"PHASE2","title":"Single-centre Study to Investigate Safety and Efficacy of Tri-Solfen in Wound Debridement","status":"UNKNOWN","sponsor":"Medical Ethics UK Ltd","startDate":"2019-01-15","conditions":["Wounds Injuries","Anesthesia, Local"],"enrollment":90,"completionDate":"2019-07-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Extracorporeal","formulation":"Liquid","formulations":[{"form":"LIQUID","route":"EXTRACORPOREAL","productName":"Dr. Zheng bacteriostatic solution"}]},"crossReferences":{"NUI":"N0000184202","MMSL":"NOCODE","NDDF":"004334","UNII":"Z7FF1XKL7A","VUID":"4020954","CHEBI":"CHEBI:39561","VANDF":"4020954","INN_ID":"2036","RXNORM":"20614","UMLSCUI":"C0055151","ChEMBL_ID":"CHEMBL1183605","KEGG_DRUG":"D03454","DRUGBANK_ID":"DB01718","PDB_CHEM_ID":"16A","PUBCHEM_CID":"2681","SECONDARY_CAS_RN":"6899-10-1","MESH_DESCRIPTOR_UI":"D000077286"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":160,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"D08AJ02","allCodes":["D08AJ02","R02AA17"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CETRIMONIUM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CETRIMONIUM is a small molecule drug that targets Dynamin-1, a protein involved in cellular processes. It belongs to the cetrimonium class and its exact commercial status is unknown. The drug's mechanism of action and approved indications are not specified. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, its clinical use and safety profile remain unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}